Evidence map›Paper›PMID 37596723›Full record

Observational studyClinical cardiology2023

Outcomes and factors associated with mortality in patients with atrial fibrillation and heart failure: FARAONIC study.

Juan José Gómez Doblas, José María Cepeda-Rodrigo, Rosa Agra Bermejo, Elvira Blanco Labrador, Maria Teresa Blasco, Margarita Carrera Izquierdo, Iñaki Lekuona, Alejandro Recio Mayoral, Carles Rafols, Nicolás Manito

Registry-linked trialOpen access · goldAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03455439 (Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03455439 completednot on this map

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

TypeobservationalSponsorBayerRan2018 to 2022Enrolled552ConditionsHeart FailureArmsRivaroxaban (Xarelto, BAY59-7939)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Juan José Gómez DoblasCardiology Department, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.ORCID https://orcid.org/0000-0002-9020-639X
José María Cepeda-RodrigoDepartment of Internal Medicine, Hospital Vega Baja, Orihuela, Spain.
Rosa Agra BermejoCardiology Department, Hospital Universitario de Santiago de Compostela, A Coruña, Spain.ORCID https://orcid.org/0000-0002-7244-9099
Elvira Blanco LabradorCardiology Department, Complexo Hospitalario de Ourense, Ourense, Spain.
Maria Teresa BlascoCardiology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Margarita Carrera IzquierdoDepartment of Internal Medicine, Complejo Asistencial Universitario de Soria, Soria, Spain.
Iñaki LekuonaCardiology Department, Hospital Galdakao-Usansolo, Bizkaia, Spain.
Alejandro Recio MayoralCardiology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Carles RafolsMedical Department, Bayer Hispania, Barcelona, Spain.
Nicolás ManitoCardiology Department, Hospital Universitario de Bellvitge, Barcelona, Spain.
Bellvitge University Hospital · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESComplejo Asistencial Universitario de Palencia · ESComplejo Hospitalario de Ourense · ESComplejo Hospitalario Universitario de Santiago · ESHospital de Galdakao · ESHospital Universitario Miguel Servet · ESHospital Universitario Virgen Macarena · ESHospital Vega Baja · ES

Funding

Bayer Hispania SL
6 · The paper itself

Abstract

backgroundHeart failure (HF) and atrial fibrillation (AF) are common and coexistent conditions. HYPOTHESIS: To investigate the adverse events and mortality risk factors in patients with AF and HF treated with rivaroxaban in Spain.

methodsMulticenter, prospective and observational study with a follow-up of 2 years, that included adults, with a diagnosis of nonvalvular AF and chronic HF, anticoagulated with rivaroxaban at least 4 months before being enrolled.

resultsA total of 672 patients from 71 Spanish centers were recruited, of whom 658 (97.9%) were included in the safety analysis and 552 (82.1%) in the per protocol analysis. At baseline, the mean age was 73.7 ± 10.9 years, 65.9% were male, 51.3% had HF with preserved ejection fraction and 58.7% were on New York Heart Association functional class II. CHA

conclusionsAmong patients with HF and AF anticoagulated with rivaroxaban, incidences of thromboembolic or hemorrhagic complications were low. The most important factor for improving survival was compliance with HF drugs, what strengths the need for early treatment with HF disease-modifying therapy and anticoagulation.

Indexed as

Atrial FibrillationHeart FailureStrokeThromboembolismAdultAgedAged, 80 and overAnticoagulantsFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsRivaroxabanAnticoagulantsRivaroxabananticoagulationatrial fibrillationdeathdirect oral anticoagulantheart failurehemorrhagerivaroxabanthromboembolismworsening heart failure

Identifiers

PMID37596723
PMCPMC10642327
OpenAlexW4385997386

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.